Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.
Epilepsy and Seizure
The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.
Patients with drug-resistant seizures should have an epilepsy center evaluation to confirm the diagnosis and determine the epilepsy syndrome and possible candidacy for neurosurgery. Guidelines here.
Patients with epilepsy often seek CAM therapies—with or without the recommendations or explicit approval of their neurologist.
Repeated brain MRI scans show four small gray matter lesions. What’s in your differential?
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
How does DBS differ from other methods of neuromodulation? This question and more in this Q&A with Dr Robert Gross, a neurosurgical primary investigator in an important trial.
Results of this Swedish study may help guide decisions about monitoring and induction of labor.
Guidelines from the American Academy of Neurology now cover the use of third-generation antiepileptic drugs for patients with new-onset focal or generalized epilepsy.
After a teenager spends 2 months in the ICU with refractory seizures, his family requests a trial of cannabidiol oil.